WASHINGTON (dpa-AFX) – Inovio (INO) said that the European Commission granted orphan drug designation for INO-3107, the company’s product candidate for the treatment of Recurrent Respiratory Papillomatosis or RRP. INO-3107 is an investigational DNA medicine candidate designed to elicit a targeted T cell response against HPV-6 and HPV-11, the HPV…Read More
Inovio EU Grants Orphan Drug Designation For INO3107
